Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,256.93
(
-1.01%
)
News Focus
News Focus
Post# of 30545
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Superfly15 post# 7212

Sunday, 06/16/2013 4:21:10 PM

Sunday, June 16, 2013 4:21:10 PM

Post# of 30545
MNTA has multiple shots on goal—generic Copaxone, FoB program, potential Lovenox-patent damages—and you’re paying almost nothing for them at the current valuation. Moreover, MNTA has ample cash* to last a long time, so you don’t have to worry about dilution.

*$344M as of 3/31/13 (including $20M of restricted cash).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today